BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2109 related articles for article (PubMed ID: 18214798)

  • 1. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.
    Tian Y; Deng YB; Huang YJ; Wang Y
    Immunol Invest; 2008; 37(1):29-42. PubMed ID: 18214798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-infusion of donor bone marrow with host mesenchymal stem cells treats GVHD and promotes vascularized skin allograft survival in rats.
    Aksu AE; Horibe E; Sacks J; Ikeguchi R; Breitinger J; Scozio M; Unadkat J; Feili-Hariri M
    Clin Immunol; 2008 Jun; 127(3):348-58. PubMed ID: 18387852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
    Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
    Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
    Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
    Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of donor CD4+CD25+ regulatory T cells on hematopoietic and immune reconstitution, GVHD and disease-free survival after allogeneic hematopoietic stem cell transplantation].
    Yang K; Fan ZP; Liu QF; Zhang Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Apr; 28(4):537-41. PubMed ID: 18495584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease.
    Yañez R; Lamana ML; García-Castro J; Colmenero I; Ramírez M; Bueren JA
    Stem Cells; 2006 Nov; 24(11):2582-91. PubMed ID: 16873762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype.
    Maccario R; Podestà M; Moretta A; Cometa A; Comoli P; Montagna D; Daudt L; Ibatici A; Piaggio G; Pozzi S; Frassoni F; Locatelli F
    Haematologica; 2005 Apr; 90(4):516-25. PubMed ID: 15820948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report.
    Zhou H; Guo M; Bian C; Sun Z; Yang Z; Zeng Y; Ai H; Zhao RC
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):403-12. PubMed ID: 19925878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulatory effects of mesenchymal stem cells involved in favoring type 2 T cell subsets.
    Lu X; Liu T; Gu L; Huang C; Zhu H; Meng W; Xi Y; Li S; Liu Y
    Transpl Immunol; 2009 Dec; 22(1-2):55-61. PubMed ID: 19695330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CM-DiI labeled mesenchymal stem cells homed to thymus inducing immune recovery of mice after haploidentical bone marrow transplantation.
    Hu KX; Wang MH; Fan C; Wang L; Guo M; Ai HS
    Int Immunopharmacol; 2011 Sep; 11(9):1265-70. PubMed ID: 21530684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of bone marrow-derived mesenchymal stem cells in reduction of graft-versus-host disease by effecting CD4+CD25+ regulatory T cells in rats].
    Tian Y; Deng YB; Huang YJ; Na XD; Li Y; Ye MH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec; 14(6):1210-4. PubMed ID: 17204196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B7.2-/- mature dendritic cells generate T-helper 2 and regulatory T donor cells in fetal mice after in utero allogeneic bone marrow transplantation.
    Bhattacharyya S; Cowan MJ
    Biol Blood Marrow Transplant; 2005 Sep; 11(9):657-71. PubMed ID: 16125636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low percentages of circulating CD8(+)/CD45RA(+) human T lymphocytes expressing beta7 integrin correlate with the occurrence of intestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Avanzini MA; Maccario R; Locatelli F; Giebel S; Santos CD; Bernardo ME; Pagliara D; Montagna D; Longo S; Amendola G; Marconi M
    Exp Hematol; 2006 Oct; 34(10):1429-34. PubMed ID: 16982336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults.
    Gonzalo-Daganzo R; Regidor C; Martín-Donaire T; Rico MA; Bautista G; Krsnik I; Forés R; Ojeda E; Sanjuán I; García-Marco JA; Navarro B; Gil S; Sánchez R; Panadero N; Gutiérrez Y; García-Berciano M; Pérez N; Millán I; Cabrera R; Fernández MN
    Cytotherapy; 2009; 11(3):278-88. PubMed ID: 19308773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth and differentiation advantages of CD4+ OX40+ T cells from allogeneic hematopoietic stem cell transplantation recipients.
    Shindo T; Ishikawa T; Fukunaga A; Hori T; Uchiyama T
    Biol Blood Marrow Transplant; 2008 Mar; 14(3):268-81. PubMed ID: 18275893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
    Taniguchi Y; Yoshihara S; Hoshida Y; Inoue T; Fujioka T; Ikegame K; Kawakami M; Masuda T; Aozasa K; Kawase I; Ogawa H
    Exp Hematol; 2008 Sep; 36(9):1216-25. PubMed ID: 18599183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation.
    Fowler DH; Odom J; Steinberg SM; Chow CK; Foley J; Kogan Y; Hou J; Gea-Banacloche J; Sportes C; Pavletic S; Leitman S; Read EJ; Carter C; Kolstad A; Fox R; Beatty GL; Vonderheide RH; Levine BL; June CH; Gress RE; Bishop MR
    Biol Blood Marrow Transplant; 2006 Nov; 12(11):1150-60. PubMed ID: 17085308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 106.